Research Analysts Offer Predictions for Tocagen Inc’s Q1 2018 Earnings (TOCA)
Tocagen Inc (NASDAQ:TOCA) – Analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for shares of Tocagen in a research report issued on Thursday. Leerink Swann analyst M. Schmidt anticipates that the company will post earnings per share of ($0.57) for the quarter. Leerink Swann also issued estimates for Tocagen’s Q2 2018 earnings at ($0.59) EPS, Q3 2018 earnings at ($0.61) EPS and Q4 2018 earnings at ($0.64) EPS.
TOCA has been the subject of several other reports. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Finally, ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $23.67.
A number of institutional investors have recently added to or reduced their stakes in the stock. Lake Street Advisors Group LLC purchased a new position in Tocagen during the fourth quarter worth about $1,042,000. TIAA CREF Investment Management LLC boosted its holdings in Tocagen by 58.4% during the fourth quarter. TIAA CREF Investment Management LLC now owns 35,994 shares of the company’s stock worth $369,000 after purchasing an additional 13,267 shares during the last quarter. Teachers Advisors LLC boosted its holdings in Tocagen by 40.7% during the fourth quarter. Teachers Advisors LLC now owns 21,163 shares of the company’s stock worth $217,000 after purchasing an additional 6,120 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Tocagen by 103.4% during the fourth quarter. California State Teachers Retirement System now owns 28,070 shares of the company’s stock worth $288,000 after purchasing an additional 14,270 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in Tocagen during the fourth quarter worth about $122,000. Institutional investors and hedge funds own 32.96% of the company’s stock.
WARNING: “Research Analysts Offer Predictions for Tocagen Inc’s Q1 2018 Earnings (TOCA)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/03/14/research-analysts-offer-predictions-for-tocagen-incs-q1-2018-earnings-toca.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.